Core Insights - Obesity is one of the top ten chronic diseases globally, with projections indicating that by 2030, the overweight and obesity rate among adults in China will reach 70.5%, and among children, it will reach 31.8% [1] - Traditional weight loss methods often lead to rebound effects and poor experiences, highlighting the need for more scientific and instinctive solutions [1] - Akk11, derived from the gut microbiota of healthy infants in pollution-free highland areas, represents a new approach to weight management by balancing metabolism and promoting gentle weight loss [1] Company and Product Development - Microbiome company has established an industry-leading fully anaerobic automated production line for Akk11, utilizing advanced technologies such as fully automated anaerobic fermentation systems and high-precision centrifugation [2] - Akk11's specifications include 600 billion AFU/gram for live bacteria and 10 trillion TFU/gram for inactivated bacteria, with an annual production capacity exceeding 200 tons, meeting market demand [2] - Akk11 is expected to receive GRAS safety certification in the United States in 2024 [2][5] Clinical Research and Efficacy - Clinical studies indicate that Akk11 effectively improves body fat, metabolic levels, and emotional health, functioning through appetite control, metabolic activation, and enhanced energy expenditure [1] - Akk11 also regulates oxidative stress, improves sleep and emotional health, creating a positive feedback loop between metabolic improvement and mental well-being [1] Market Potential and Future Outlook - Akk11 has garnered global attention in the health industry, particularly at the 2025 Natural Products Expo West in the United States, showcasing its potential beyond weight loss, including benefits for blood pressure stability and bone health [6] - The product has multiple patents and clinical research supporting its effects on blood lipid regulation, liver protection, and anti-aging, indicating a broad application prospect [6] - The company aims to continue focusing on promoting human health and environmental sustainability through high-quality microbiota [7]

郜恒骏致辞时回顾了生物芯片上海国家工程研究中心自2001年成立以来的发展历程，感谢以烟台毓璜顶 医院宋西成教授等为代表的山东医疗界同仁在中国医药生物技术协会组织生物样本库分会耳鼻咽喉头颈 外科学组筹建(宋西成教授当选为首届组长)、山东省生物样本库联盟打造以及全国生物样本库质量和能 力认可准则培训等工作中给予的大力支持。目前，中心已在山东布局肠道微生态诊疗、治病及学科运营 三大中心，此次烟台分中心的成立是重要落地成果之一。 齐鲁晚报.齐鲁壹点孙淑玉通讯员李成修李添祎 5月11日，由烟台毓璜顶医院主办的山东省半岛微生态医学与粪菌移植论坛在烟台举行。生物芯片上海 国家工程研究中心主任、中国幽门螺杆菌分子医学中心主任郜恒骏，南京医科大学第二附属医院副院 长、微生态医学科主任张发明，烟台毓璜顶医院党委书记、院长宋西成，山东省医学会消化病学分会主 任委员、山东省立医院消化内科主任许洪伟等专家出席。论坛由烟台毓璜顶医院党委副书记刘杰主持， 来自全国的顶尖专家学者齐聚一堂，围绕肠道微生态医学前沿进展、粪菌移植技术标准化及临床应用等 核心议题展开深入研讨。 宋西成在开幕式致辞中指出，肠道微生态研究作为全球生命科学的热点领域，其 ...